XBiotech (NASDAQ:XBIT) Shares Pass Below Fifty Day Moving Average – Should You Sell?

XBiotech Inc. (NASDAQ:XBIT) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.43 and traded as low as $2.40. XBiotech shares last traded at $2.42, with a volume of 44,015 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of XBiotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, XBiotech currently has a consensus rating of “Sell”.

XBiotech Stock Down 0.8%

The company has a market cap of $73.79 million, a price-to-earnings ratio of -1.83 and a beta of 0.88. The company’s fifty day moving average price is $2.43 and its two-hundred day moving average price is $2.44.

XBiotech (NASDAQ:XBIT) last released its quarterly earnings results on Thursday, May 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.21).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its holdings in shares of XBiotech by 41.5% in the second quarter. Bank of America Corp DE now owns 18,208 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 5,344 shares during the period. XTX Topco Ltd acquired a new position in shares of XBiotech in the second quarter valued at approximately $61,000. BNP Paribas Financial Markets boosted its holdings in shares of XBiotech by 27.1% in the second quarter. BNP Paribas Financial Markets now owns 20,729 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 4,416 shares during the period. Jane Street Group LLC acquired a new position in shares of XBiotech in the second quarter valued at approximately $75,000. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of XBiotech by 50.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 89,547 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 30,000 shares during the period. Institutional investors and hedge funds own 55.70% of the company’s stock.

About XBiotech

XBiotech Inc is a clinical-stage biopharmaceutical company developing human antibodies to treat cancer and other inflammatory-driven diseases. The company’s core technology, the True Human™ antibody platform, enables the discovery and development of monoclonal antibodies that mimic the human immune response without the need for genetic humanization. XBiotech’s lead therapeutic candidate targets interleukin-1 alpha (IL-1?), a key mediator of inflammation associated with tumor growth and chronic disease.

The company’s most advanced program, Xilonix® (MABp1), is a first-in-class anti-IL-1? antibody that has completed Phase 3 clinical trials in metastatic colorectal cancer patients.